Literature DB >> 17961878

Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.

Bolyn Hubby1, Todd Talarico, Maureen Maughan, Elizabeth A Reap, Peter Berglund, Kurt I Kamrud, Laura Copp, Whitney Lewis, Chad Cecil, Pamela Norberg, Jordan Wagner, Aubrey Watson, Sarah Negri, Bruce K Burnett, Andrew Graham, Jonathan F Smith, Jeffrey D Chulay.   

Abstract

We used a propagation-defective, single-cycle, alphavirus replicon vector system to produce virus-like replicon particles (VRP) expressing the hemagglutinin (HA) and neuraminidase (NA) proteins from influenza A/Wyoming/03/2003 (H3N2). Efficient production methods were scaled to produce pilot lots of HA VRP and NA VRP and clinical lots of HA VRP. HA VRP-induced high-titered antibody responses in mice, rabbits and rhesus macaques, as measured by ELISA or hemagglutination inhibition (HI) assays, and robust cellular immune responses in mice and rhesus macaques, as measured by IFN-gamma ELISPOT. NA VRP also induced cellular immune responses in mice. A toxicology study with HA VRP and NA VRP in rabbits showed no adverse effects in any parameter. These studies support clinical testing of alphavirus replicon vaccines for influenza.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17961878      PMCID： PMC2706696          DOI： 10.1016/j.vaccine.2007.09.038

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  20 in total

1.  Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine.

Authors:  Alan Coulter; Rodney Harris; Roslyn Davis; Debbie Drane; John Cox; David Ryan; Phil Sutton; Steve Rockman; Martin Pearse
Journal:  Vaccine       Date:  2003-02-14       Impact factor: 3.641

2.  Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo.

Authors:  P M Taylor; B A Askonas
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

3.  Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus.

Authors:  K L Yap; G L Ada; I F McKenzie
Journal:  Nature       Date:  1978-05-18       Impact factor: 49.962

4.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Authors:  D Hobson; R L Curry; A S Beare; A Ward-Gardner
Journal:  J Hyg (Lond)       Date:  1972-12

5.  Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses.

Authors:  J J Treanor; K Kotloff; R F Betts; R Belshe; F Newman; D Iacuzio; J Wittes; M Bryant
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

6.  Cytotoxic T-cell immunity to influenza.

Authors:  A J McMichael; F M Gotch; G R Noble; P A Beare
Journal:  N Engl J Med       Date:  1983-07-07       Impact factor: 91.245

7.  Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection.

Authors:  K R Beutner; T Chow; E Rubi; J Strussenberg; J Clement; P L Ogra
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

Review 8.  Are we ready for pandemic influenza?

Authors:  Richard J Webby; Robert G Webster
Journal:  Science       Date:  2003-11-28       Impact factor: 47.728

9.  Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

Authors:  Matthew R Sandbulte; Gretchen S Jimenez; Adrianus C M Boon; Larry R Smith; John J Treanor; Richard J Webby
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

10.  Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells.

Authors:  M Eichelberger; W Allan; M Zijlstra; R Jaenisch; P C Doherty
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307
View more
  29 in total

Review 1.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

2.  In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs.

Authors:  Kurt I Kamrud; V McNeil Coffield; Gary Owens; Christin Goodman; Kim Alterson; Max Custer; Michael A Murphy; Whitney Lewis; Sarah Timberlake; Elizabeth K Wansley; Peter Berglund; Jonathan Smith
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

3.  Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles.

Authors:  Daniel R Tonkin; Alan Whitmore; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2012-04-21       Impact factor: 3.641

Review 4.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer.

Authors:  Michael A Morse; Amy C Hobeika; Takuya Osada; Peter Berglund; Bolyn Hubby; Sarah Negri; Donna Niedzwiecki; Gayathri R Devi; Bruce K Burnett; Timothy M Clay; Jonathan Smith; H Kim Lyerly
Journal:  J Clin Invest       Date:  2010-08-02       Impact factor: 14.808

6.  Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity.

Authors:  Yasushi Uematsu; Michael Vajdy; Ying Lian; Silvia Perri; Catherine E Greer; Harold S Legg; Grazia Galli; Giulietta Saletti; Gillis R Otten; Rino Rappuoli; Susan W Barnett; John M Polo
Journal:  Clin Vaccine Immunol       Date:  2012-05-23

7.  Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.

Authors:  Douglas S Reed; Pamela J Glass; Russell R Bakken; James F Barth; Cathleen M Lind; Luis da Silva; Mary Kate Hart; Jonathan Rayner; Kim Alterson; Max Custer; Jeanne Dudek; Gary Owens; Kurt I Kamrud; Michael D Parker; Jonathan Smith
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

8.  Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.

Authors:  Jay W Hooper; Anthony M Ferro; Joseph W Golden; Peter Silvera; Jeanne Dudek; Kim Alterson; Max Custer; Bryan Rivers; John Morris; Gary Owens; Jonathan F Smith; Kurt I Kamrud
Journal:  Vaccine       Date:  2009-10-13       Impact factor: 3.641

9.  Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies.

Authors:  George Jiang; Meng Shi; Solomon Conteh; Nancy Richie; Glenna Banania; Harini Geneshan; Anais Valencia; Priti Singh; Joao Aguiar; Keith Limbach; Kurt I Kamrud; Jonathan Rayner; Jonathan Smith; Joseph T Bruder; C Richter King; Takafumi Tsuboi; Satoru Takeo; Yaeta Endo; Denise L Doolan; Thomas L Richie; Walter R Weiss
Journal:  PLoS One       Date:  2009-08-10       Impact factor: 3.240

10.  Development and characterization of promoterless helper RNAs for the production of alphavirus replicon particle.

Authors:  K I Kamrud; K Alterson; M Custer; J Dudek; C Goodman; G Owens; J F Smith
Journal:  J Gen Virol       Date:  2010-02-24       Impact factor: 3.891
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.